 |
The Whole Care NetworkHelping You Tell Your Story One Podcast at a Time Author: The Whole Care Network Language: en Genres: Business, Entrepreneurship, Personal Journals, Society & Culture Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
From Practice to Purpose: Dr. Mark Goldstein's Journey into Alzheimer's Research
Friday, 1 May, 2026
In this episode of the WCNFluencer podcast, host Christopher MacLellan interviews Dr. Mark Goldstein, a founding member of GEM Research. Throughout the episode, Christopher and Dr. Goldstein discuss Dr. Goldstein's transition from private practice to a focus on clinical trials, particularly in Alzheimer's. The conversation covers the importance of clinical trials, the distinction between Alzheimer's and dementia, recognizing symptoms, current treatments, hereditary factors, and the broader research focus at JEM Research Institute. Dr. Goldstein emphasizes the need for early intervention and the potential for future breakthroughs in Alzheimer's treatment. Takeaways - Dr. Goldstein transitioned from private practice to clinical trials. - Clinical trials are essential for developing new medications. - Dementia is a broader term, with Alzheimer's being a major type. - Recognizing early symptoms is crucial for caregivers. - Biomarkers can help diagnose Alzheimer's earlier than before. - Current treatments slow progression but are not cures. - Hereditary factors can increase the risk of Alzheimer's. - GEM Research conducts trials for various neurological conditions. - Combination therapies may be the future of Alzheimer's treatment. - Participation in clinical trials is free and private. To learn more about Dr. Goldstein and JEM Research Institute, click HERE!
